



Prague, 22 April 2020

Ref. No.: MZDR 17206/2020-1/MIN/KAN

MZDRX01A0LSG

EXTRAORDINARY MEASURE

The Ministry of Health, as the competent administrative authority, pursuant to Section 80(1)(g) of Act No. 258/2000 Coll., on Public Health Protection and the amendment to certain related acts, as amended (hereinafter referred to as “Act No. 258/2000 Coll.”), **orders** this extraordinary measure, proceeding pursuant to Section 69(1)(i) and (2) of Act No. 258/2000 Coll., in order to protect the population and prevent the occurrence and spread of the COVID-19 disease caused by the new SARS-CoV-2 coronavirus:

I.

The following healthcare service providers:

- General University Hospital in Prague,
 - University Hospital Brno,
 - University Hospital Olomouc,
 - Krajská zdravotní, a. s.,
 - Institute for Clinical and Experimental Medicine (IKEM)
- are ordered to conduct the SARS-CoV-2-CZ-Preval Collective Immunity Study, the protocol of which is published at <https://covid-imunita.uzis.cz/> (hereinafter referred to as the “study”).

II.

For the purposes of conducting the study specified in paragraph I, the healthcare service providers specified in paragraph I are ordered:

- a) to collect samples for the purposes of the study at the study testing tents, arranged (with the exception of the Institute for Clinical and Experimental Medicine) by the Czech Army in accordance with the Study Protocol and Rules of Operation of study testing tents at the following locations:
- General University Hospital in Prague
 - Náměstí Míru, Prague
 - Zítkovy sady, Prague
 - Kateřinská zahrada near Viničná Street, Prague
 - University Hospital Brno
 - Moravské náměstí, Brno,
 - Masaryk University Campus near Netroufalky Street, Brno,

- **University Hospital Olomouc**
 - Area in front of the Globus hypermarket, Pražská Street, Olomouc,
 - Area in front of the Billa supermarket, Příčná Street, Litovel,
 - Náměstí Osvobození, Uničov
 - **Krajská zdravotní, a. s.**
 - Zahrada Čech Exhibition Grounds, Na Vinici, Litoměřice,
 - **Institute for Clinical and Experimental Medicine (IKEM)**
 - IKEM Compound, Vídeňská Street, Prague,
- b) ensure staff to perform the collection of capillary blood, and potentially venous blood, and subsequent testing for the presence of antibodies against coronavirus using rapid tests based on the study protocol,
- c) ensure the coordination of activities and training of staff working at the study testing tent,
- d) indicate the laboratory evaluation of swabs for the presence of coronavirus using PCR tests for positively diagnosed individuals via the IHIS CR electronic application form,
- e) ensure cooperation in procuring medical material for conducting the study at the testing tent,
- f) ensure cooperation in disposing of biological material and waste from the study testing tents after the collection of this material by the Czech Army,
- g) ensure cooperation with the implementer of the study, the Institute of Health Information and Statistics of the Czech Republic, data quality monitoring and evaluation of the study.

III

This extraordinary measure is issued with effect from 12:00 a.m. on 23 April 2020.

IV

This extraordinary measure takes effect on the date of its issue.

Rationale:

This extraordinary measure is issued in connection with the implementation of measures to limit the spreading of COVID-19 disease caused by the novel coronavirus identified as SARS-CoV-2 in the Czech Republic.

An obligation is stipulated for selected key healthcare services providers to participate in conducting the SARS-CoV-2-CZ-Preval Collective Immunity Study. The COVID-19 disease is caused by the novel coronavirus experts have named SARS-CoV-2. It is a highly infectious disease, which is manifested primarily by fevers, respiratory problems, muscle pain and fatigue. However, despite the publication of hundreds of articles in specialised literature,

fundamental information about the spread and course of the COVID-19 disease is still lacking. One such crucial piece of information is the prevalence of asymptomatic individuals with the SARS-CoV-2 infection, which has a major impact on the dynamics of spreading the COVID-19 disease in the Czech Republic and within individual regions and locations.

The aim of the SARS-CoV-2-CZ-Preval study is to quantify the prevalence of individuals with past SARS-CoV-2 coronavirus infections in the Czech Republic, excluding those in whom COVID-19 was diagnosed by methods based on direct proof of the SARS-CoV-2 virus, including individuals with sub-clinical progression of the disease. The data will be evaluated by a team from IHIS CR and cooperating academic institutions pursuant to a statistical analysis.

To ensure a sufficient number of valid references for this study, it is necessary to stipulate the rules for obtaining them and manner of performing the related activities. Given the stipulated purpose, healthcare service providers who will ensure the high-quality performance of this study were selected.

Mgr. et Mgr. Adam Vojtěch, MHA
Minister of Health

Signed electronically